[HTML][HTML] Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
C Hölscher - Neuropharmacology, 2024 - Elsevier
Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
C Hölscher - Neuropharmacology, 2024 - europepmc.org
Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
[PDF][PDF] Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
C Hölscher - Neuropharmacology, 2024 - researchgate.net
Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
C Hölscher - Neuropharmacology - pubmed.ncbi.nlm.nih.gov
Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …